glp 1 agonists vs sglt2 inhibitors GLP-1 Receptor Agonist Therapy With and Without in Patients With Type 2 Diabetes View of Diabetes medications with

Incretin hormones: revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity

And as indicated by the list above of upcoming trials, there may be several new indications in the near future

Evidence-based GLP-1 care Custom-formulated compounded medications using ingredients commonly prescribed in medical practice

Mann JFE, Rossing P, Bakris G et al

*Correspondence: Daiji Kawanami, [email protected] This article was submitted to Renal Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers